Cancer is being increasingly recognised as a metabolic, as well as genetic, disease which introduces a need to further investigate the metabolic changes which transformed cells (cancerous cells) must undergo to survive the adverse tumour microenvironment conditions created during the disease, and how oncogenes and tumour suppressors affect this process. Mitochondria have been recognised as key machinery involved in metabolic remodelling during cancer. These organelles play a crucial role in energy production within the cell and defects in this production is believed to lead to cancer. These defects are sometimes due to mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA.
Transmit aims to investigate the metabolic remodelling in human cancers, focusing on mitochondria, which will bridge basic research to improved development of potential therapies. The project will also communicate this emerging field to the patients and their families.
A network of world-leading scientific centres, industry SMEs, non-profit foundations and cancer care associations will work together throughout the course of the project, to allow the transfer of knowledge from all related fields. Eleven early-stage researchers will be trained using these scientific and technical advances to unravel the metabolic features of cancer as well as providing a portfolio of transferrable skills which will improve the multidisciplinary training and education of young research scientists.
For more information on the Transmit Project, click the logo below.